NORCROSS, GA. — SpectRx
has received another grant from the National Cancer Institute for further development of a non-invasive test for cervical cancer.
SpectRx received some $690,000 in its fifth award. So far, the company has received $3.2 million.
The latest funds are to be used to complete the ongoing clinical trial for the test, SpectRx said. The trial has enrolled more than 1,100 women and is expected to be finished next year.
"We believe that this level of continued support from the NCI is an important validation of our technology for the early detection of cervical disease," said Mark Faupel, chief technical officer of SpectRx